Welcome to our dedicated page for Retractable Tech SEC filings (Ticker: RVP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Retractable Technologies, Inc. (RVP) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Retractable’s filings, including Form 10-K annual reports, Form 10-Q quarterly reports, and Form 8-K current reports, describe its business of manufacturing and marketing VanishPoint®, EasyPoint®, and Patient Safe® safety medical products, as well as key financial and operational details.
In its periodic reports, Retractable discusses net sales, operating income or loss, domestic and international revenue mix, and the influence of product mix between VanishPoint® syringes and EasyPoint® needles on average selling prices and margins. The filings also address the material impact of tariffs on needles, syringes, and other products imported from China, and explain how these costs are reflected in cost of manufactured product. Disclosures describe the company’s efforts to increase U.S.-based manufacturing, adapt equipment for domestic production, and adjust its workforce in response to tariff pressures.
Form 8-K current reports for RVP document material events such as quarterly and annual results announcements, preferred stock dividend declarations for Series II Class B and Series III Class B Convertible Preferred Stock, workforce reductions, and product-related recognitions. These filings confirm that Retractable’s common stock is registered on NYSE American under the symbol RVP and that the company is incorporated in Texas.
On Stock Titan, users can review these SEC filings with AI-powered summaries that highlight key points from lengthy documents, such as discussions of tariffs, product mix, liquidity considerations, and risk factors related to patent protection, supplier relationships, foreign trade risk, access to markets, production costs, and competition from larger safety device providers. The platform also surfaces updates in near real time as new filings are posted to EDGAR, helping users quickly see changes in Retractable’s reported results, capital structure, or material events.
By combining the full text of RVP’s SEC filings with AI-generated explanations, this page is intended to make it easier to understand how Retractable’s safety medical device business, financial performance, and risk disclosures are presented in its official regulatory documents.
Retractable Technologies, Inc. (RVP) Form 4 shows that Thomas J. Shaw, who serves as President & CEO, Director and a greater-than-10% owner, executed a purchase of 9,042 shares of the company's common stock under a Rule 10b5-1 plan at a weighted average price of $0.7963 per share. After the transaction, Mr. Shaw beneficially owns 15,645,325 shares directly and 831,600 shares indirectly (the indirect shares reflect his investment power as Trustee for a family member and voting control under a voting agreement). The filing discloses the 10b5-1 plan adoption date as August 22, 2024.
Thomas J. Shaw, President, CEO and director of Retractable Technologies, Inc. (RVP), reported an insider purchase under a Rule 10b5-1 plan. On 08/18/2025 Mr. Shaw acquired 32,935 shares of the company at a weighted-average price of $0.795 per share. Following the transaction he beneficially owns 15,636,283 shares directly and 831,600 shares indirectly, with indirect holdings reflecting trustee investment power and a voting agreement described in the filing. The Form 4 was executed under a 10b5-1 plan adopted August 22, 2024 and was signed by an attorney-in-fact on 08/19/2025.
Retractable Technologies (RVP) Form 4: Thomas J. Shaw, President, CEO, Director and 10% owner, reported two open-market purchases executed under a Rule 10b5-1 plan. On 08/14/2025 he purchased 3,103 shares at a weighted average price of $0.7875. On 08/15/2025 he purchased 10,980 shares at a weighted average price of $0.7948. Following these transactions Mr. Shaw beneficially owns 15,603,348 shares directly and has indirect beneficial ownership of 831,600 shares (investment power as trustee over 500,000 shares and voting control over the remainder by agreement). The 10b5-1 plan was adopted on August 22, 2024.
Retractable Technologies, Inc. filed an Form 8-K dated August 14, 2025 disclosing an Item 8.01 other event and Item 9.01 exhibits. The filing attaches a press release that announces results for the periods ended June 30, 2025. The document is signed by John W. Fort III, Vice President, Chief Financial Officer, and Chief Accounting Officer, and lists Little Elm, Texas as the company's principal executive office.
Retractable Technologies, Inc. (RVP) reported net sales of $10.45 million for the quarter and $18.74 million for the first six months of 2025, up from $6.03 million and $13.63 million a year earlier. Unit growth was driven by higher EasyPoint® needle volumes, but average selling prices fell due to product mix and distributor transaction fees, producing a small quarterly gross loss of $0.11 million and a six-month gross loss of $0.42 million.
The company recorded a six-month net loss of $10.59 million versus $13.74 million a year earlier. Investment holdings were $30.0 million at fair value (down from $40.3 million), producing a $5.6 million unrealized investment loss YTD. Cash totaled $3.04 million and inventories were $20.45 million. Other long-term liabilities under the Technology Investment Agreement (TIA) were $60.92 million. Tariffs from Chinese imports materially increased costs—approximately $2.1 million YTD—with second-quarter tariff expense of $561 thousand. The company received $1.9 million in litigation settlement proceeds and sold $5.0 million of securities to support operations.
Thomas J. Shaw, President & CEO and director of Retractable Technologies, Inc. (RVP), acquired 3,983 shares of the issuer's common stock at a weighted average price of $0.8015 under a Rule 10b5-1 plan. After the reported purchase, Mr. Shaw directly beneficially owned 15,593,248 shares and held indirect beneficial ownership of 831,600 shares through arrangements that include trustee investment power and a voting agreement.
The filing identifies Mr. Shaw as a director, officer and a greater-than-10% owner and states the 10b5-1 plan was adopted on August 22, 2024. The disclosed transaction was reported on Form 4 and was filed by one reporting person.
Thomas J. Shaw, identified as President & CEO, Director and a 10% owner of Retractable Technologies, Inc. (RVP), reported a transaction executed under a Rule 10b5-1 plan. On 08/12/2025 he acquired 8,411 shares of common stock at a weighted-average price of $0.823. Following the reported transaction, he is shown as directly beneficially owning 15,589,265 shares.
In addition to direct holdings, the filing discloses 831,600 shares of indirect beneficial ownership described as voting or investment control; the filing notes Mr. Shaw has investment power over 500,000 shares as trustee for a family member and voting control over the remainder pursuant to a voting agreement. The 10b5-1 plan was adopted on 08/22/2024, indicating the trade was part of a pre-arranged program rather than an ad hoc transaction.
Thomas J. Shaw, President & CEO, Director and 10% owner of Retractable Technologies (RVP), reported an acquisition of 2,100 common shares on 08/11/2025 under a Rule 10b5-1 plan at a weighted average price of $0.8118. After this transaction he beneficially owns 15,580,854 shares directly and 831,600 shares indirectly. The filing explains the indirect holdings include investment power over 500,000 shares as Trustee and voting control over the remainder pursuant to a voting agreement. The Rule 10b5-1 plan was adopted on August 22, 2024.
Thomas J. Shaw, President, CEO, Director and reported 10% owner of Retractable Technologies, Inc. (RVP), reported a transaction dated 08/07/2025 showing an acquisition of 49,541 shares of common stock at a weighted average price of $0.747. Following the reported transaction, the filing lists 15,578,754 shares beneficially owned directly and 831,600 shares beneficially owned indirectly.
The filing explains Mr. Shaw has investment power over 500,000 shares as trustee for a family member and retains voting control over the remainder under a voting agreement. The remarks note a Rule 10b5-1 plan adoption date of August 22, 2024. The form is signed by an attorney-in-fact on 08/11/2025.